Medpace, a privately held, global, full-service contract research organization (CRO) announced that it has acquired MediTech Strategic Consultants B.V. (MediTech), a European CRO dedicated to medical device clinical trials and services related to development and commercialization of medical devices.
MediTech joins Medpace as a strategic European acquisition, expanding Medpace’s European device capabilities both in the development of trial designs and regulatory strategies towards CE Mark, in addition to the conduct of clinical trials and authorized representative and quality system support towards ISO 13485. This acquisition, combined with Medpace’s existing medical device division, provides a unique global solution for medical device development, allowing seamless support through all stages of the medical device lifecycle.
MediTech was founded in 2000 by Carla Kikken-Jussen, President & CEO, an industry expert with over 25 years of experience in the medical device industry covering medical device clinical research and European regulatory affairs. MediTech has supported clinical trials on wide variety of medical devices including therapeutic areas such as ophthalmology, cardiovascular, gastroenterology, orthopedics, and pulmonology medical devices. Ms. Kikken-Jussen will continue to lead MediTech with her team members, bringing extensive experience to Medpace.
"I am pleased to welcome Carla Kikken-Jussen and the MediTech team to Medpace,‖ said Dr. August Troendle, President and CEO, Medpace. ―MediTech’s expertise complements and broadens our global medical device service offering. MediTech is well respected in both Europe and the US and this strategic acquisition fully supports Medpace’s growth and provides our sponsors a wide range of regulatory and clinical expertise across North America and Europe along with expanded operational capacity."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.